The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. While https://nicolexonr476756.csublogs.com/46614373/glp-3-retatrutide-a-comparative-analysis